Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2018-01-08
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT02220608
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2016-03-30
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 32
- Registration Number
- NCT02221492
- Locations
- 🇯🇵
Investigational Site Number 392005, Chiba-Shi, Japan
🇯🇵Investigational Site Number 392010, Hamamatsu-Shi, Japan
🇯🇵Investigational Site Number 392003, Kobe-Shi, Japan
Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2015-08-04
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 14
- Registration Number
- NCT02221479
- Locations
- 🇯🇵
Investigational Site Number 392105, Kamogawa-Shi, Japan
🇯🇵Investigational Site Number 392103, Kyoto-Shi, Japan
🇯🇵Investigational Site Number 392104, Okayama-Shi, Japan
A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02190721
- Locations
- 🇷🇴
Teva Investigational Site 52063, Bucharest, Romania
🇺🇸Teva Investigational Site 12957, Houston, Texas, United States
🇭🇺Teva Investigational Site 51186, Budapest, Hungary
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-06-30
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 237
- Registration Number
- NCT02177695
- Locations
- 🇺🇸
Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States
🇺🇸Green Bay Oncology - Oconto Falls, Oconto Falls, Wisconsin, United States
🇺🇸Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States
REaCT Integrated Consent Model to Compare Two Standard of Care Regimens
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 142
- Registration Number
- NCT02173262
- Locations
- 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
- First Posted Date
- 2014-06-19
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Rafic Farah, MD
- Target Recruit Count
- 28
- Registration Number
- NCT02167958
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Gcsf Injection in Women With Repeated Implantaiton Failure
- First Posted Date
- 2014-05-29
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Clinique Ovo
- Target Recruit Count
- 15
- Registration Number
- NCT02149277
- Locations
- 🇨🇦
Clinique Ovo, Montreal, Quebec, Canada
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 70
- Registration Number
- NCT02143830
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 167
- Registration Number
- NCT02124148
- Locations
- 🇺🇸
Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States
🇺🇸Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.